Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Background: While third-generation EGFR tyrosine kinase inhibitors (TKI) like aumolertinib have significantly improved outcomes for patients with advanced lung adenocarcinoma, those harboring the L858R mutation still experience inferior prognosis compared to those with exon 19 deletions. Recent evidence suggests that combining TKIs with chemotherapy improves progression-free survival (PFS), but universal application of this combination exposes all patients to cytotoxic toxicity, even those who might thrive on TKI monotherapy alone. Circulating cell-free DNA (cfDNA) and minimal residual disease

Trial Details

NCT ID
NCT07624487
Phase
PHASE2
Sponsor
Taipei Medical University Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin)
Locations (sample)
  • New Taipei City, Taiwan|25.06199,121.45703
  • Taipei, Taiwan|25.05306,121.52639
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Individuals must be at least 18 years of age at the time of signing the informed consent form.
  • Participants must demonstrate the ability to understand the study procedures and provide written informed consent before any trial-specific activit…
  • A confirmed diagnosis of lung adenocarcinoma (LUAD) via histological or cytological examination is required. The disease must be in an advanced or …
  • Documentation of an EGFR L858R mutation is mandatory. This status can be confirmed using tumor tissue or plasma-based molecular testing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →